1. Introduction
===============

Dementia, also classified as neurocognitive disorder in Diagnostic and Statistical Manual of Mental Disorders Fifth Edition, is a group of degenerative neurological disorders that are disturbance of multiple higher cortical functions, and is characterized by progressive decline of cognitive function and interference of daily living activities.^\[[@R1],[@R2]\]^ Approximately, 35.6 million people currently suffer from dementia worldwide and this number is estimated to rise to 65.7 million in 2030.^\[[@R3]\]^ Alzheimer disease (AD), which is the most frequent type of dementia, requires the biggest medical expenses among the 10 major geriatric diseases. Its pathological hallmarks are amyloid plaque, neurofibrillary tangles, and neuronal and synaptic loss.^\[[@R4]\]^ Vascular dementia (VD), which is induced by cerebrovascular pathology, is the second most common form of dementia. Current studies found that relation among neuron, glia, and vascular cells attributes to cognitive impairment in VD.^\[[@R5]\]^

Acetylcholine esterase inhibitors (eg, donepezil, rivastigmine, and galantamine) or *N*-methyl-D-aspartate receptor antagonist (eg, memantine) is currently used to stall or delay the progression of both AD and VD, but these medications cannot fully treat any form of the disease.^\[[@R6],[@R7]\]^ Many pharmaceutical companies rushing to develop next-generation anti-dementia medications have to deal with challenges such as a variety of mechanism such as neuronal damage caused by acetylcholine synthesis, amyloid beta protein deposition, and hyperphosphorylation of tau protein. Many drug candidates were successful in animal experiments, but did not prove to be effective in clinical trials. For this reason, researchers turned their attention to natural resources or herbal formulae that can simultaneously act on multiple targets, rather than a single compound focusing on a certain mechanism. EGb 761 (Tanakan), the extract of *Ginkgo biloba*, has been used in traditional medicine to treat cognitive disorders such as AD.^\[[@R8]\]^ Huperzine A, alkaloid compound in *Huperzia serrata*, was proven to be acetylcholine esterase inhibitor and *N*-methyl-D-aspartate receptor antagonist.^\[[@R9]\]^ In phase II trial for mild-to-moderate AD patients, the dose of 400 μg/d Huperzine A did not show significant effect but the higher dose of 800 μg/d showed cognitive improvement.^\[[@R10]\]^ Regarding VD, China has made it a national priority to proceed with a phase IV clinical trial of Tian zhi granule, derived from a traditional Chinese herbal formula.

Given the current trend of mining natural resources for anti-dementia drug candidates, Danggui-Shaoyao-San (DSS) could be viewed as another promising medication to treat dementia. DSS, one of the most widely used formula, is called Toki-shakuyaku-san in Japan and Dangguijakyakan in Korea. DSS was first introduced in "Synopsis of Prescriptions of the Golden Chamber," ![](medi-99-e18507-i001.jpg) and it consists of *Angelica gigas*, *Paeonia lactiflora*, *Ligusticum chuanxiong*, *Poria cocos*, *Atractylodes macrocephala*, and *Alisma orientalis*. DSS is sold on the market as TJ-23 (Tsumura) and K-15 (Kracie Pharma, Ltd.) in Japan, Tang-Kuei & Peony Formula (Sun Ten Pharmaceutical Co.) in Taiwan, and as Dangguijakyaksan (Hankook Shinyak Pharmaceutical Co., Ltd., Kyungjin Pharm, Co., Ltd., etc) in Korea.

As one of the basic formula in traditional medicine, DSS can be a useful preventive or therapeutic agent for cognitive decline. This widely used formula has many reports of a cognitive function from Japan.^\[[@R11],[@R12]\]^ Korean researchers presented long-term case series on mild cognitive impairment (MCI).^\[[@R13]\]^ In Korea, 1 pharmaceutical company has developed an extract of *A gigas*, one of the main ingredients of DSS, as a therapeutic agent for AD and has completed phase III trials.^\[[@R14],[@R15]\]^ With the aim to validating the efficacy of DSS on dementia, we have conducted a systematic review on DSS and meta-analyses of its efficacy regarding cognition and other functions.

2. Methods
==========

2.1. Search strategy and eligibility criteria
---------------------------------------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and recommendations of the Cochrane Collaboration were followed for the reporting of this review ([www.prisma-statement.org](http://www.prisma-statement.org/)) (Fig. [1](#F1){ref-type="fig"}). We searched online databases such as PubMed, Embase, Korean databases (Research Information Service System and Oriental Medicine Advanced Searching Integrated System), Chinese databases (China Knowledge Resource Integrated Database and Wanfang Database), and Japanese databases (CiNii and J-STAGE) from inception to June 2019. The search terms were adapted to suit each database. For PubMed, we used the following search strategy: {("Dangguijakyaksan"\[tiab\] OR "toki-shakuyaku-san"\[tiab\] OR "Danggui Shaoyao Powder"\[tiab\] OR "TJ-23"\[tiab\] OR "Dangguijakyak-san"\[tiab\]) OR ("*Angelica gigas*"\[tw\] AND "*Paeonia lactiflora*"\[tw\]) OR (*Angelica*\[tw\] AND Peony\[tw\]) OR "Danggui-Shaoyao-San"\[mh\] OR "toki-shakuyaku-san"\[mh\]} AND (dementia\[tiab\] OR "mild cognitive impairment"\[tiab\] OR MCI\[tiab\] OR Alzheimer\[tiab\] OR "Pick disease"\[tiab\] OR "Pick\'s disease"\[tiab\] OR "lewy body"\[tiab\] OR memory\[tiab\] OR cognitive\[tiab\] OR dementia\[mh\] OR "memory disorders"\[mh\] OR "cognitive dysfunction"\[mh\]).

![. Study flow diagram. DSS = Danggui-Shaoyao-San, OASIS = Oriental Medicine Advanced Searching Integrated System, RISS = Research Information Service System.](medi-99-e18507-g001){#F1}

Studies were included if they

1.  were a randomized controlled trial (RCT);

2.  investigated the efficacy of DSS or its modified form that the author mentioned originates from DSS and comprises *A gigas*, *P lactiflora*, *L chuanxiong*, *P cocos*, *A macrocephala*, and *A orientalis*; and

3.  included participants with dementia (AD, VD, Lewy body dementia, Pick disease). Use of DSS with other treatment (eg, acupuncture, anti-dementia drugs, etc) was included.

Studies were excluded if they met any of the following criteria:

1.  the difference of intervention group and control group is the component other than DSS;

2.  studies did not use outcome measures of interest;

3.  studies were not published either in English, Korean, Chinese, or Japanese; or

4.  studies reported duplicate data.

Ethical approval was not necessary in this study as we used aggregated data from the included studies.

2.2. Data extraction and items
------------------------------

Two reviewers independently reviewed the titles and abstracts. Irrelevant or duplicate articles were removed in this step. The abstracts of the remaining articles were reviewed using the eligibility criteria. If the abstract did not provide sufficient information, the full-text article was reviewed. One reviewer conducted a full abstraction of all data, and 2 reviewers verified accuracy. The identification of relevant studies is presented in Figure [1](#F1){ref-type="fig"}. Data from each eligible study were extracted, and details of the author, publication year, location, participant characteristics, setting, intervention, duration of intervention, control, outcome measures, adverse events, and assessment of risk of bias were placed in summary tables (Table [1](#T1){ref-type="table"}). The risk of bias was independently assessed using the Cochrane Risk of Bias Assessment Tool^\[[@R16]\]^ by 2 authors. An "unclear" judgment was made if the insufficient detail was provided.

###### 

Characteristics of RCTs of Danggui-Shaoyao-San for dementia.

![](medi-99-e18507-g002)

2.3. Outcome measures and analysis
----------------------------------

The primary outcome measures were scales for dementia such as Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale (HDS). Secondary outcome measures were activities of daily living (ADL) and the improvement rate of symptoms that assessed the change of dementia symptom determined by criteria from "Guiding principle of clinical research on new drugs of traditional Chinese medicine."^\[[@R17]\]^

For the meta-analysis, in terms of pooled results, continuous data were expressed as mean differences (MD) and dichotomous data were presented as odds ratios with associated 95% confidence intervals (CI). MD for changes of each outcome measure was used. If the trial reported only the value at pretreatment and that at posttreatment, the mean change was subtracting pre-measurement from post-measurement. If the standard deviation (*s.d*) for change was missing, it was calculated using the following formula. 

The correlation coefficients between pre- and post-measurements (*r*~pre,post~) were calculated from a study with detailed value^\[[@R18]\]^ in synthesis of AD studies with comparison with vitamin E or was assumed to be 0.5^\[[@R19],[@R20]\]^ in synthesis of VD studies. Random-effects model was used because the number of participants of the included studies was small. *I*^2^ statistic was used to present statistical heterogeneity. Due to its small number of included studies, the existence of publication bias was not assessed. Meta-analysis was performed using RevMan 5.3.5 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).

3. Results
==========

3.1. Characteristics of included studies
----------------------------------------

Among 482 relevant articles identified in the initial search, 9 studies^\[[@R21]--[@R29]\]^ met our inclusion criteria and were subjected to our systematic review. A flow chart detailing the search and screening process can be found in Figure [1](#F1){ref-type="fig"}. We excluded 446 studies by removing duplicates and screening. We collected remaining 36 studies as full-text articles to evaluate eligibility and we excluded 27 studies with reasons (no comparison group,^\[[@R30]--[@R40]\]^ review articles,^\[[@R41]--[@R47]\]^ used different or multiple herbal formula as intervention,^\[[@R48]--[@R50]\]^ report on the result from the same cohort,^\[[@R51],[@R52]\]^ no focus on cognitive function,^\[[@R53],[@R54]\]^ no report on detailed value of outcomes,^\[[@R55]\]^ ingredient of modified DSS was not revealed^\[[@R56]\]^). Table [1](#T1){ref-type="table"} summarizes the characteristics of the included studies in terms of patients' age, duration of disease, and elements of study quality. These studies enrolled 567 patients with a mean study size of 63 patients, with ages ranging from 40 to 85 years. The duration that the studies lasted ranged from 4 to 24 weeks. Five studies^\[[@R21]--[@R25]\]^ were subjected to AD, and the rest of them^\[[@R26]--[@R29]\]^ were to VD. Outcome measures used by the researchers of enrolled studies were mostly scales of dementia (eg, MMSE,^\[[@R21]--[@R24],[@R26]--[@R29]\]^ HDS^\[[@R23]--[@R27]\]^), ADL,^\[[@R21]--[@R24]\]^ and improvement rate of symptoms.^\[[@R23],[@R24],[@R27]--[@R29]\]^

DSS was orally administered in the form of aqueous extract in every included study. Modified prescription respectively added *Codonopsis pilosula* Radix,^\[[@R25]\]^*Polygonatum sibiricum*,^\[[@R28]\]^*Cistanche deserticola*, *Cuscutae Semen*, *Polygala tenuifolia*, *Alpiniae Fructus*, *Acorus gramineus* Solander,^\[[@R27],[@R29]\]^ and other additional herbs according to traditional medical diagnosis (pattern differentiation).^\[[@R24]\]^ DSS was administered 3 times a day in 3 studies,^\[[@R25],[@R27],[@R29]\]^ and twice a day in the rest of the studies.^\[[@R21]--[@R24],[@R26],[@R28]\]^ Two studies assessed the efficacy of treatment by both DSS and acupuncture.^\[[@R23],[@R24]\]^ No studies reported the case of cointervention of DSS with anti-dementia drugs. Two^\[[@R21],[@R22]\]^ out of 5 AD studies that assessed single effect of DSS were compared with vitamin E and 1 study^\[[@R25]\]^ was compared with Huperzine A. Two AD studies that assessed the effect of both DSS and acupuncture^\[[@R23],[@R24]\]^ were compared with acupuncture alone,^\[[@R23],[@R24]\]^ DSS alone,^\[[@R23]\]^ or calcium channel blocker, nimodipine.^\[[@R23]\]^ All the included VD studies were compared with nootropic drugs that were of racetam groups^\[[@R26],[@R28]\]^ or dual use of Duxil and Citicoline.^\[[@R27],[@R29]\]^

All eligible studies were parallel, open RCTs, and their risk of bias is reported in Table [1](#T1){ref-type="table"}. All the included studies did not mention the detail of randomization and were at high risk of bias in regard to blinding.

3.2. Synthesis of studies of DSS for AD
---------------------------------------

All RCTs reported positive effects of DSS on AD.^\[[@R21]--[@R25]\]^ Meta-analyses of 2 studies comparing DSS with vitamin E resulted in significant difference in both MMSE (MD 4.60; 95% CI 4.29, 4.91, Z = 28.72, *P* \< .001) and ADL (MD 11.40; 95% CI 10.94, 11.86, Z = 48.49, *P* \< .001) with low heterogeneity (*I*^2^ = 0%) (Fig. [2](#F2){ref-type="fig"}).

![. Forest plot of comparison of clinical efficacy in Danggui-Shaoyao-San versus vitamin E on Alzheimer disease. ADL = activities of daily living, MMSE = Mini-Mental State Examination.](medi-99-e18507-g004){#F2}

Two studies focused on cointervention of DSS and acupuncture versus acupuncture.^\[[@R23],[@R24]\]^ Pooled results showed that scores of MMSE (MD 1.69; 95% CI 1.05, 2.23, Z = 5.15, *P* \< .001, *I*^2^ = 7%) and ADL (MD 2.38; 95% CI 1.92, 2.85, Z = 10.08, *P* \< .001, *I*^2^ = 0%) differed significantly between DSS combined with acupuncture and acupuncture only. HDS tended to be in favor of cointervention, but it was not statistically significant (MD.62; 95% CI --0.20, 1.44, Z = 1.48, *P* = .14) with relatively higher heterogeneity (*I*^2^ = 31%) than other analyses (Fig. [3](#F3){ref-type="fig"}). The odds of enhancing symptom with DSS and acupuncture were 2.14 times higher (95% CI 0.99, 4.64, Z = 1.93, *P* = .05, *I*^2^ = 0%) than those with acupuncture alone in elderly with AD.

![. Forest plot of comparison of clinical efficacy in Danggui-Shaoyao-San and acupuncture versus acupuncture alone on Alzheimer disease. ADL = activities of daily living, AT = acupuncture treatment, CI = confidence intervals, DSS = Danggui-Shaoyao-San, HDS = Hasegawa Dementia Scale, IV = intravenous, MMSE = Mini-Mental State Examination, SD = standard deviation.](medi-99-e18507-g005){#F3}

3.3. Synthesis of studies of DSS for vascular dementia
------------------------------------------------------

Four VD studies^\[[@R26]--[@R29]\]^ were selected, and they all included comparison with nootropics as a control. Nootropics used in the trials were Piracetam,^\[[@R26]\]^ Oxiracetam,^\[[@R28]\]^ and Duxil and Citicoline injection.^\[[@R27],[@R29]\]^ In the analysis of MMSE from 3 studies,^\[[@R26],[@R27],[@R29]\]^ the width of CI decreased (MD 3.07; 95% CI 1.71, 4.43, Z = 4.43, *P* \< .001). Two studies^\[[@R26],[@R27]\]^ reported modest positive change of HDS (MD 2.57; 95% CI 0.53, 4.61, Z = 2.47, *P* = .01) (Fig. [4](#F4){ref-type="fig"}A). All 4 RCTs^\[[@R26]--[@R29]\]^ (n = 270) were included in the improvement rate of symptoms analysis. Oral administration of DSS significantly increased the odds of improvement rate of symptoms by 4 times (odds ratio 5.02; 95% CI 2.76, 9.11, Z = 5.29, *P* \< .001) comparing with nootropic drugs (Fig. [4](#F4){ref-type="fig"}B). The *I*^2^ statistic in every meta-analysis did not identify the presence of heterogeneity among the studies (*I*^2^ = 0%).

![. Forest plot of comparison of clinical efficacy in Danggui-Shaoyao-San versus nootropics on vascular dementia. (A) Comparison of MMSE and HDS and (B) comparison of improvement rate of symptoms are presented. CI = confidence intervals, HDS = Hasegawa Dementia Scale, IV = intravenous, MMSE = Mini-Mental State Examination, SD = standard deviation.](medi-99-e18507-g006){#F4}

3.4. Adverse events
-------------------

Adverse events were not specifically reported in most studies. One study mentioned adverse events that the Huperzine A, which was used as control, had mild nausea, whereas DSS had no adverse event.^\[[@R25]\]^

4. Discussion
=============

The current systematic review and meta-analysis compares the efficacy of DSS on dementia in elderly. There were 2 main findings. First, in cognition and ADL of AD, DSS was better than vitamin E supplement and has a synergistic effect when used with acupuncture. Second, DSS had a more beneficial effect than nootropic drugs on cognitive impairment of VD. No adverse event was reported. To the best of our knowledge, this is the first systematic review and meta-analysis of a certain type of herbal formula for AD while there barely exists a systematic review on a single type of herb or herbal prescription for cognitive function of dementia patients. Systematic reviews previously conducted on herbal medicine for dementia analyzed multiple types of herbal medicines and they were not free from heterogeneity.^\[[@R57]--[@R59]\]^ They also mostly focused on herbal prescriptions that are only purchasable in China or studied on behavioral and psychological symptoms. DSS, the widely available formula, has been investigated for cognitive impairment since the late 1980s in east Asian countries either by experiments or by clinical studies. The current evidence from this systematic review demonstrated that DSS could improve symptoms of dementia patients in clinical practice.

In this study, DSS worked both on cognitive function of AD and on VD as presented in MMSE and HDS scores. Although the RCT for MCI was not included in this research, several previous studies regarding MCI also imply that DSS might enhance cognitive function. Ninety-five MCI patients who administered DSS twice a day showed significantly higher MMSE and Montreal Cognitive Assessment after the intervention, and its effect persisted in 1-year follow-up.^\[[@R13]\]^ Its efficacy on cognitive impairment was also assessed using brain imaging tools in observational studies. DSS improved decreased alpha activity of AD and VD patients in electroencephalography.^\[[@R37]\]^ Some MCI cases were reported that patients who were treated by DSS for 8 weeks had improved regional cerebral blood flow on single photon emission computed tomography imaging.^\[[@R11]\]^ DSS made regional cerebral blood flow in the posterior cingulate higher in MCI and AD patients' brain, and orientation score in MMSE also improved.^\[[@R12]\]^

Furthermore, according to the results of this review, DSS not only affected cognitive function but also improved ADL. Aside from this, even though only 2 RCTs systemically assessed,^\[[@R25],[@R28]\]^ most observational studies reported that DSS effectively diminished behavioral and psychological symptoms such as wandering, agitation, hyperactivity, insomnia, delusion, and depressive mood.^\[[@R30],[@R34],[@R36]--[@R40]\]^ DSS diminishes the possibility of geriatric depression that is raised as an intermediary of dementia.^\[[@R60]\]^ In the 1-year follow-up study on MCI, DSS improved Geriatric Quality of Life-Dementia and Geriatric Depression Scale-Korean.^\[[@R13]\]^ This fact implies that DSS not only simply improves memory but also works on global function. DSS can be suggested as a potential agent for multiple symptoms of dementia including cognitive impairment, BPDS, and other accessory symptoms.

According to previous pharmacological researches, DSS was reported to have a neuroprotective effect on neuronal damage and regain reduced long-term potentiation induced by neurotoxicity of amyloid beta protein.^\[[@R61]--[@R63]\]^ DSS had a positive effect on free radical-mediated neurological disorders, showed anti-inflammatory and antioxidant activities, and reduced cell apoptosis in the hippocampus.^\[[@R64],[@R65]\]^ DSS have an influence on synthesizing and releasing neurotransmitter including acetylcholine, dopamine, and norepinephrine.^\[[@R64],[@R66],[@R67]\]^ It also shown neuroprotective effect in microglia cell inflammation^\[[@R68]\]^ or in neuronal damage caused by hypoglycemia/hypoxia^\[[@R69]\]^ and glutamate.^\[[@R70],[@R71]\]^ Individual herbal components were previously studied regarding cognition. INM-176, ethanolic extract of *A gigas*, improved cognitive impairment in scopolamine and amyloid beta protein models of mice by acetylcholine esterase inhibition and neuroprotection.^\[[@R14]\]^ This agent also completed phase III trial for Alzheimer type dementia.^\[[@R72]\]^*P lactiflora* was superior to *Angelica* root in terms of memory decline, both of which significantly improved performance in radial maze in AD mouse model.^\[[@R73]\]^ Paeonol, which is the ingredient of root of *P lactiflora*, improved cognitive decline and neurodegeneration in hippocampus and cortex, and it was supported by its antioxidant effect.^\[[@R74]\]^ Paeoniflorin, also isolated from the root of *P lactiflora*, ameliorated ischemic pathology and neurological symptoms including cognitive impairment in middle cerebral artery occlusion model of rat.^\[[@R75]\]^ The series of results potentially implies that DSS has a neuroprotective effect and can be another candidate for agents of AD and VD.

This wide range that DSS works on reminds us of 2 possibilities of DSS. One is that DSS operates on multitarget as revealed in a previous system pharmacology study.^\[[@R76]\]^ Second is that DSS may act on a fundamental mechanism that contributes to brain function related to both AD and VD rather than specific pathology of each disease such as amyloid beta protein and tau.

DSS was more effective than vitamin E that can be considered as placebo,^\[[@R77]\]^ and its efficacy is, thus, promising in AD. Even though DSS was superior to Huperzine A regarding cognitive function and dementia-related condition,^\[[@R25]\]^ comparison with commonly used anti-dementia drugs or combining use with them should be investigated further. The difference between DSS combined with acupuncture and acupuncture alone was not as remarkable as that between DSS and vitamin E in AD, and difference of HDS did not differ significantly. As acupuncture is reported to have a therapeutic effect on dementia,^\[[@R78],[@R79]\]^ this may attribute to ceiling effect of treating dementia. The relatively higher value of *I*^2^ in MMSE and HDS comparing with other analyses might be owing to different types of acupuncture that were body acupuncture^\[[@R23]\]^ and electroacupuncture.^\[[@R24]\]^

Regarding its noticeable effect on VD, DSS basically has a positive effect on cerebrovascular diseases. DSS improved both hemorheological abnormalities and cognitive function in VD patients.^\[[@R26]\]^ On a 1-year RCT, DSS helped in the recovery of stroke patients and reduced its worsening.^\[[@R53]\]^ In case series of asymptomatic cerebral infarction, microcirculation of bulbar conjunctiva improved and hemorheological factors also significantly changed after administration of DSS.^\[[@R80]\]^

The RCTs included in this study did not report adverse effect of DSS. Most observational studies also did not report adverse effect so it was hard to confirm whether DSS had no risk. Assessment of adverse effect found in some observational studies, though, helped us assume its possible side effect. Two studies that tested 8-week administration of DSS neither showed abnormality in laboratory examination nor subjective/objective symptom.^\[[@R12],[@R36]\]^ Eighty cases of AD or VD who were administered DSS for 12 weeks report nothing other than decrease of average blood pressure and decrease of average serum sodium level within normal range.^\[[@R38]\]^ Two cases of indigestion occurred among 95 MCI patients who took DSS for 12 weeks.^\[[@R13]\]^ Safety of DSS could be suggested considering these cases of the elderly, even though elaborately designed RCT should be performed in the future.

We also acknowledge the limitations of this review. The number of RCTs was small, and the respective size of the trial was also small. In the case that the included studies were of the small number, we were unable to assess risk of bias across studies. As they were all written by Chinese authors, potential publication bias may be considered. Since all the studies did not fully describe methodological issues, they were of low quality, or they have barely undergone an adequate assessment of the risk of bias. Every included study was randomized in parallel, but the exact method of randomization was not designated. Blinding was hardly conducted at least in terms of participants. Most studies had short duration varying from 4 to 12 weeks, but its long-term efficacy and side effect need to be investigated as dementia agents are prescribed for a longer period.

Limitations aside, this review provides important evidence that DSS is effective for major types of dementia. Based on the available evidence, DSS showed a considerable change on cognitive function and accompanied symptoms of dementia with low risk of side effect. Accordingly, practitioners can consider DSS as another option for AD and VD.
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